Ernest Nadal-Alforja

Author

Also Known As

Ernest Nadal-Alforja

Publications

688

Citations

H-Index

Concepts

All Affiliations

Ernest Nadal-Alforja is an author at Institut Català d'Oncologia specializing in radiation oncology, cancer therapeutics, and oncology.

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	686
2	Health Sciences	2	2	92
3	Pathology	1	1	594
4	Radiation Medicine	1	1	24
5	Surgical Oncology	1	1	68

Ernest Nadal-Alforja

Publications

686

Citations

H-Index

Page 1

	Year	Citations
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG. Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo, Journal of Clinical Oncology Surgical OncologyMedicineHigh Response RateNeoadjuvant TreatmentAdjuvant Treatment	2018	68
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. Solange Peters, Dirk De Ruysscher, Urania Dafni, Journal of Clinical Oncology Concurrent Immune-checkpoint InhibitionPharmacotherapyImmunotherapyRadiation MedicineOncology	2018	24

Page 1